445TiP VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state

Abstract

The improvements in the systemic control of metastatic colorectal cancer (CRC) motivate doctors and patients (pts) to pursue the no evidence of disease state (NED) via locoregional treatments independently of the line of treatment and the classical guidelines indications. Standard treatments for the stage IV NED condition include surveillance despite a relapse rate of approximately 80-90% or perioperative/adjuvant FOLFOX for those pts who have never received chemotherapy before. Early-phase trials have shown a potential synergic effect of the VEGFR tirosin-kinase inhibitor Regorafenib combined with anti PD-1 agents in advanced gastrointestinal cancers.